TWD
NTLA icon

True Wealth Design’s Intellia Therapeutics NTLA Stock Holding History

True Wealth Design’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23
Closed -$295 – 2814
2026
Q1 		$295 Buy
+23
New +$293 ﹤0.01% 2225
2025
Q4 		– Sell
-24
Closed -$415 – 2743
2025
Q3 		$415 Hold
24
– – ﹤0.01% 2064
2025
Q2 		$226 Sell
24
-73
-75% -$599 ﹤0.01% 2038
2025
Q1 		$690 Buy
+97
New +$980 ﹤0.01% 1422

Other funds holding NTLA

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

True Wealth Design's NTLA Position: Q2 2026 in Review

True Wealth Design sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 23 shares — an estimated $295 sold.

True Wealth Design first reported a position in NTLA in Q1 2025 and held it in 4 quarters. The position peaked at $690 in Q1 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • True Wealth Design reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • True Wealth Design sold 23 Intellia Therapeutics shares in Q2 2026, an estimated $295.
  • True Wealth Design first reported a position in Intellia Therapeutics in Q1 2025 and held it in 4 quarters.
  • True Wealth Design's Intellia Therapeutics position peaked at $690 in Q1 2025.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.